Key result
This review summarizes current antiplatelet therapies and innovative approaches to targeting protease-activated receptors in patients with atherothrombotic vascular disease.
Population
Patients with atherothrombotic vascular disease
Design
Review
Authors
Loading...
May guide antiplatelet strategies in atherothrombotic disease; leaves open PAR-targeting efficacy pending prospective trials.
This review discusses current antiplatelet therapies and innovative approaches targeting protease-activated receptors (PARs) in atherothrombotic vascular disease.
Holinstat et al. (2015) conducted a review in Atherothrombotic vascular disease. Protease-activated receptor (PAR) antagonism was evaluated. This review summarizes current antiplatelet therapies and innovative approaches to targeting protease-activated receptors in patients with atherothrombotic vascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: